Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma:a Randomized, Multicenter, Phase II Trial

NCT05097209 is registered in ClinicalTrials.gov with Wei Jiang as lead sponsor.

NCT NCT05097209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05097209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma:a Randomized, Multicenter, Phase II Trial
Lead sponsor
Wei Jiang
Phase
Phase 2
Overall status
Unknown status
Start date
April 6, 2022
Completion date
April 6, 2026
Enrollment
200 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal carcinoma